Antidiabetic effects of hesperidin and naringin in type 2 diabetic rats

Diabetologia Croatica

Volumn 41, Issue 2, 2012, Pages 53-67

  Ahmed, Osama M ^a,b   Mahmoud, Ayman M ^a   Abdel Moneim, Adel ^a   Ashour, Mohamed B ^a  

^a Beni Suef University   (Egypt)

^b Beni Suef   (Egypt)

Author keywords

Adiponectin; Hesperidin; Insulin resistance; Naringin; Resistin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AURANTIIN; CHOLESTEROL; CREATINE KINASE ISOENZYME; GLUCOSE; GLYCOGEN; GLYCOSYLATED HEMOGLOBIN; HESPERIDIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; LACTATE DEHYDROGENASE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; GLYCOGEN MUSCLE LEVEL; HEART FUNCTION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; STREPTOZOCIN DIABETES;

EID: 84867612534     PISSN: 03510042     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33:(Suppl 1):S62-S69.
2. Taskinen MR. Diabetic dyslipidemia. Atheroscl Suppl 2002;3:47-51.
3. Jenson T, Stender, Deckert T. Abnormalities in plasma concentration of lipoprotein and fibrinogen in type 1 (insulin dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1998;31:142-146.
4. Moller D. New drug targets for type 2 diabetes and the metabolic syndrome: a review. Nature 2004;414:821-827.
5. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-1053.
6. Cheng D. Prevalence, predisposition and prevention of type II diabetes. Nutr Metab (Lond) 2005;2:29.
7. The use of animal models in diabetes research. 2012 Feb 21. doi: 10.1111/j.1476- 5381.2012.01911.x. [Epub ahead of print]
8. Jazet IM, Pijl H, Meinders AE. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth J Med 2003;61(6):194-212.
9. Lu H, Wang H, Wen Y, et al. Roles of adipocyte derived hormones adiponectin and resistin in insulin resistance of type 2 diabetes. World J Gastroenterol 2006;12(11):1747-1751.
10. Milner B, Marc J, Janez A, Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007;375:20-35.
11. MacDougald O, Burant CF. The rapidly expanding family of adipokines. Cell Metab 2007;6(3):159-161.
12. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-769.
13. Verges B, Petit JM, Duvillard L, Dautin G, et al. Adiponectin is an important determinant of apoAI catabolism. Arterioscler Thromb Vasc Biol 2006;26:1364-1369.
14. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 2003;52:1779-1785.
15. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Matab 2008;34:2-11.
16. Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-175.
17. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004;255(4):439-447.
18. Hoseen MI, Hassan MM, Abd-Alaleem DI, Faragallah EM. Serum resistin levels and haemostatic changes in experimentally induced diabetic and high fat fed rats. J Am Sci 2010;6(11):217-227.
19. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature 2001;409(6818):307-312.
20. Rajala MW. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004;114:232-239.
21. Norata GD, Ongari M, Garlaschelli K, Raselli SL AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007;156:279-284.
22. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistinlike molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003;111:225-230.
23. Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean Atherosclerosis Study (KAS): a 42-month prospective study. Atherosclerosis 2008;196(1):398-404.
24. Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacol Ther 2010;125:328-361.
25. Chen H, Ward MH, Graubard BI. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr 2002;75:137-144.
26. Jung UJ, Lee MK, Jeong KS, Choi MS. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. 2004;134(10):2499-2503.
27. Canadian Council on Animal Care. Guide to the care and use of experimental animals, Vol. 2. Ottawa, Ontario, Canada: CCAC, 1993.
28. Srinivasan K, Viswanand B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low dose of streptozotocin- treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005;52:313-320.
29. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, et al. A new rat model of type 2 diabetes, the fat-fed, streptozotocin-treated rat. Metabolism 2000;49:1390-1394.
30. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 1969;6:24-27.
31. Little RR, Wiedmeyer HM, England JD, Wilke AL, Rohlfing CL, Wians FH, et al. Interlaboratory standardization of measurements of glyco - hemoglobins. Chem 1992;38:2472-2478.
32. Seifter S, Dayton S, Novic B, Muntwyler E. The estimation of glycogen with anthrone reagent. Arch Biochem 1950;25:191-200.
33. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959-965.
34. American Diabetic Association Consensus Development Conference on Insulin Resistance, November 5-6, 1997. Diabetes Care 1998;21:310-314.
35. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-684.
36. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20(4):470-475.
37. nd ed. Philadelphia, PA: W.B. Saunders Co., 1990.
38. Harris RJ. Plasma nonesterified fatty acid and blood glucose levels in healthy and hypoxemic newborn infants. Pediatrics 1974;84:578-584.
39. Venugopala Rao A, Ramakrishan S. Indirect assessment of hydroxymethylglutaryl CoA reductase (NADPH) activity in liver tissue. Clin Chem 1975;21(10):1523-1525.
40. Friedewald WT. Estimation of concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18(7):499-502.
41. rd edition. Philadelphia, PA: W.B. Saunders Co., 1995.
42. International Federation of Clinical Chemistry, Scientific Committee. J Clin Chem Clin Biochem 1980;18:521-534.
43. Teitz N, editor. Fundamentals of clinical chemistry. Philadelphia, PA: W. B. Saunders Co., 1986.
44. nd ed. Philadelphia, PA: W. B. Saunders Co., 1976;682.
45. th ed. Philadelphia, PA: W. B. Saunders Co., 1992;1106-1124.
46. Roa M, Blane K, Zonneberg M. One way analysis of variance. Version IA (C). PC-STAT, Program coded by University of Georgia, USA, 1985.
47. Chandramohan G, Ignacimuthu S, Pugalendi KV. A novel compound from Casearia esculenta (Roxb.) root and its effect on carbohydrate metabolism in streptozotocin-diabetic rats. Eur J Pharmacol 2008;590:437-443.
48. Saravanan G, Ponmurugan P. Ameliorative potential of s-allyl cysteine on oxidative stress in STZ induced diabetic rats. Chemico-Biological Interactions 2010; doi:10.1016/j.cbi.2010.10.001.
49. Ramachandran S, Asokkumar K, Uma Maheswari M, Ravi TK., Sivashanmugam AT., Saravanan S, et al. Investigation of antidiabetic, antihyperlipidemic, and in vivo antioxidant properties of Sphaeranthus indicus Linn. in type 1 diabetic rats: an identification of possible biomarkers. Evidence-Based Complem Altern Med 2011; doi:10.1155/2011/571721.
50. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia and hypertension: parallels between human disease and rodent models. Diabetes Care 1991;14:195-202.
51. Zhang F, Ye C, Li G, Ding W, Zhou W, Zhu H, et al. The rat model of type 2 diabetes mellitus and its glycometabolism characters. Exp Animals 2003;52:401-407.
52. Schaalan M, El-Abhar HS, Barakat M, El-Denshary ES. Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. J Diabetes Complications 2009;23:199-208.
53. Ahmed OM, Abdel-Moneim A, Abulyazid I, Mahmoud AM. Antihyperglycemic, anti - hyperlipidemic and antioxidant effects and the probable mechanisms of action of Ruta graveolens and rutin in nicotinamide/streptozotocin diabetic albino rats. Diabetol Croat 2010;39:15-32.
54. Farswan M, Mazumder PM, Parcha V. Modulatory effect of an isolated compound from Syzygium cumini seeds on biochemical parameters of diabetes in rats. Int J Green Pharm 2009;3:128-133.
55. Beck-Nielsen H. Insulin resistance: organ manifestations and cellular mechanisms. Ugeskr Laeger 2002;164:2130-2135.
56. Gold AH. The effect of diabetes and insulin on liver glycogen synthetase activation. J Biol Chem 1970;245:903-905.
57. Raju J, Gupta D, Rao AR, Yadava PK, Baquer NZ. Trigonella foenum graecum (fenugreek) seed powder improves glucose homeostasis in alloxan diabetic rat tissues by reserving the altered glycolytic, gluconeogenic and lipogenic enzymes. Mol Cell Biochem 2001;224:45-51.
58. th ed. McGraw- Hill Co. Inc., 2005.
59. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-789.
60. Song H, Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, et al. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Biochem Biophys Res Commun 2002;29:291-298.
61. Jung UJ, Lee MK, Jeong KS, Choi MS. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J Nutr 2004;134:2499-2503.
62. Pari L, Suman S. Antihyperglycemic and antilipid peroxidative effects of flavonoid naringin in streptozotocin-nicotinamide induced diabetic rats. Int J Biol Med Res 2010;1:206-210.
63. Akiyama S, Katsumata S, Suzuki K, Ishimi Y, Wu J, Uehara M. Dietary hesperidin exerts hypoglycemic and hypolipidemic effects in streptozotocin-induced marginal type 1 diabetic rats. J Clin Biochem Nutr 2010;46:87-92.
64. Sheela CG, Augusti KT. Antidiabetic effects of Sallyl cysteine sulphoxide isolated from garlic, Allium sativum Linn. Ind J Exp Biol 1992;30:523-526.
65. Goldstein DE. How much do you know about glycated hemoglobin testing. Clin Diabetes 1995;13:60-63.
66. Choi EJ. Antioxidative effects of hesperidin against 7,12-dimethylbenz(a)anthracene-induced oxidative stress in mice. Life Sci 2008;82:1059-1064.
67. Singh D, Chander V, Chopra K. Protective effect of naringin, a bioflavonoid on ferric nitrilotriacetateinduced oxidative renal damage in rat kidney. Toxicology 2004;201:1-8.
68. Grover JK, Vats V, Rathi SS. Antihyperglycemic effect of Eugenia jambolana and Tinospora cordifolia in experimental diabetes and their effects on key metabolic enzymes involved in carbohydrate metabolism. J Ethnopharmacol 2000;73:461-470.
69. Lavoie L, Van de Werve G. Hormone-stimulated glucose production from glycogen in hepatocytes from streptozotocin diabetic rats. Metabolism 1991;40:1031-1036.
70. Pari L, Murugan P. Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol 2005;16:257-274.
71. Pushparaj PN, Low HK, Manikandan J, Tan BKH, Tan CH. Anti-diabetic effects of Cichorium intybus in streptozotocin-induced diabetic rats. J Ethno - pharmacol 2007;111:430-434.
72. Wold LE, Ceylan IAF, Ren J. Oxidative stress and stress signaling: menace of diabetic cardio - myopathhy. Acta Pharmacol Sinica 2005;26:908-917.
73. Keenoy BMY, Campenhout VA, Aerts P, Vertommen, Abrams P, Gaal LFV, et al. Time course of oxidative stress status in the postprandial and postabsorptive states in type 1 diabetes mellitus: relationship to glucose and lipid changes. J Am College Nutr 2005;24:474-485.
74. Ravi K, Rajasekaran S, Subramanian S. Antihyperlipidemia effect of Eugenia jambolana seed kernel on streptozotocin-induced diabetes in rats. Food Chem Toxicol 2005;43:1433-1439.
75. Tan BKH, Tan CH, Pushparaj PN. Anti-diabetic activity of the semi-purified fractions of Averrhoa bilimbi in high fat diet fed streptozotocin-induced diabetic rats. Life Sci 2005;76:2827-2839.
76. Zhang W, Zhao J, Wang J, Pang X, Zhuang X, Zhu X, Qu W. Hypoglycemic effect of aqueous extract of sea buckthorn (Hippophae rhamnoides L.) seed residues in streptozotocin-induced diabetic rats. Phytother Res 2010;24:228-232.
77. Gorinstein S, Vargas OJM, Jaramillo NO, Salas IA, Ayala ALM, et al. The total polyphenols and the antioxidant potentials of some selected cereals and pseudocereals. Eur Food Res Technol 2007;225:321-328.
78. Knekt P, Kumpulainen J, Jarvinen R. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002;76:560-568.
79. Baldeweg SE, Golay A, Natali A, Balkau B, Del Prato S, Coppack SW. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. Eur J Clin Invest 2002;30:45-52.
80. Abdin AA, Baalash AA, Hamooda HE. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers. J Diabetes Complications 2010;24:168-178.
81. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 2003;52:1-8.
82. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995;44:863-870.
83. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23(2):201-229.
84. Na LX, Zhang YL, Li Y, Liu LY, Li R, Kong T, Sun CH. Curcumin improves insulin resistance in skeletal muscle of rats. Nutr Metab Cardiovasc Dis 2010;21(7):1-8.
85. Raz I, Eldor R, Cernea S, Shafrir E. Diabetes, insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 2005;21:3-14.
86. Haffner M. Coronary heart disease in patients with diabetes. N Engl J Med 2000;342:1040.
87. Garber AJ. Attenuating CV risk factors in patient with diabetes: clinical evidence to clinical practice. Diabetes Obes Metab 2002;4:S5.
88. Grover SA, Levington C, Paquet S. Identifying adults at low risk for significant hyperlipidemia: a validated clinical index. J Clin Epidemiol 1999;52:49.
89. Sugiura M, Ohshima M, Ogawa K, Yano M. Chronic administration of Satsuma mandarin fruit improves oxidative stress in streptozotocin induced diabetic rat liver. Biol Pharmacol Bull 2006;29:588-591.
90. Kushiyama A, Shojima N, Ogihara T, Inukai K, Sakoda H, Fujishiro M. Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet. J Biol Chem 2005;280:42016-42025.
91. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW. Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 2004;114:232-239.
92. Moon B, Kwan JJ, Duddy N, Sweeney G, Begum N. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab 2003;285:E106-115.
93. Ferrer JC, Favre C, Gomis RR, Fernaóndez- Novell JM, Garcýóa-Rocha M, de la Iglesia N. Control of glycogen deposition. FEBS Lett 2003;546:127-132.
94. Xu W, Yu L, Zhou W, Luo M. Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun 2006;351:376-382.
95. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2002;1:81-88.
96. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
97. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang CC, Itani SI, et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 2002;99:16309-16313.
98. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2006;281:2654-2660.